Biovail Settles Cardizem Suit With Watson Unit
Under the agreement, Andrx, a subsidiary of Watson Pharmaceuticals Inc., may not begin to market generic diltiazem extended-release tablets until April 1, 2009.
Neither a Biovail nor an Andrx spokesperson would disclose more about the terms of the settlement on Tuesday.
The settlement must first...
To view the full article, register now.